Industry Pulse: 10 charts on M&A, I/O and biosimilar threats

12:24 EDT 1 Sep 2017 | BioPharmaDive

While Gilead's acquisition of Kite has lifted the biotech sector, major dealmaking has so far been few and far between this year. Elsewhere, copycat biologics pose a growing threat to industry top-sellers. 

Original Article: Industry Pulse: 10 charts on M&A, I/O and biosimilar threats


More From BioPortfolio on "Industry Pulse: 10 charts on M&A, I/O and biosimilar threats"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...